Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female engineer named Morgan Beller.Technologyread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Agricultureread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Moving lots of data to a public cloud over the internet can take months or years. CNBC got an inside look at how AWS transfers data to the cloud for its clients.Technologyread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
The president also said he "offered to personally vouch" for Rocky's bail. Sweden, however, does not have a bail system.Politicsread more
CoinShares Chief Strategy Officer Meltem Demirors discusses Facebook's Libra project and its impact on the cryptocurrency market after testifying to the House Financial...Fast Moneyread more
Some 40% of Americans would struggle to come up with even $400 to pay for an emergency expense. Just how are so many Americans so short on cash? Blame debt.Personal Financeread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
The bull market is "in trouble," strategist Alicia Levine told CNBC on Monday.
U.S. stocks continued to fall on Monday, with large tech stocks leading the way down. The action came after equities posted sharp weekly losses on Friday.
"There is probably another leg down from here," said Levine, chief investment strategist at BNY Mellon. The firm has $1.8 trillion of assets under management.
"If it can hold the low levels of 2018 then you could move higher, but right now we just see a very messy and unsatisfying market," she told "Power Lunch. "
The hit its 52-week low of 2,532.69 during the February sell-off.
Levine pointed out that large-cap tech names, which drove the market higher, became 25 percent of the S&P 500 in August. Now with those stocks dropping, the index needs the other 75 percent to carry it.
"It's a math problem. It's very hard to get that kind of performance to move the index up," she said.
And she isn't holding out hope that tech stocks will rebound, calling the sector "broken."
She said the multiples and price philosophy has been predicated on exponential growth, which just isn't going to be there going forward.
"It's coming back down to Earth, and I don't think we're done yet," Levine predicted.
Michael Arone, chief market strategist at State Street, doesn't see the end of the bull market, yet.
"The fat lady is certainly not singing just yet to signal the end of this bull market," he said on "Power Lunch." However, "in the background, you can hear her warming up."
Right now, investors are pricing in the worst-case scenarios for U.S.-China trade relations, fiscal stimulus wearing off, Federal Reserve rate hikes and the slowing corporate profits, explained Arone, whose firm has $2.7 trillion of assets under management.
Therefore, if there is any type of relief in those areas, the market could rebound heading into next year, he added.
As for where to look when investing, BNY Mellon's Levine said she likes the services aspect of health care. She said hospitals, HMOs and Medicaid HMOs look attractive, in part because the midterm election results, which will have Democrats taking control of the House of Representatives in January, mean Obamacare will not be repealed. Plus in some states Democrats will take over as governor from outgoing Republicans, which could mean an expansion in Medicaid, she said.
She said she doesn't like biotech or pharmaceuticals because of all the "noise" over pricing.